Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Parkinsonian Disorders HELP
Based on 35,859 articles published since 2008
|||| 16 

These are the 35859 published articles about Parkinsonian Disorders that originated from Worldwide during 2008-2019.
 
+ Citations + Abstracts
Pages: 1 · 2 · 3 · 4 · 5 · 6 · 7 · 8 · 9 · 10 · 11 · 12 · 13 · 14 · 15 · 16 · 17 · 18 · 19 · 20
1 Guideline Collective physician perspectives on non-oral medication approaches for the management of clinically relevant unresolved issues in Parkinson's disease: Consensus from an international survey and discussion program. 2015

Odin, P / Ray Chaudhuri, K / Slevin, J T / Volkmann, J / Dietrichs, E / Martinez-Martin, P / Krauss, J K / Henriksen, T / Katzenschlager, R / Antonini, A / Rascol, O / Poewe, W / Anonymous2260838. ·Department of Neurology, Lund University Hospital, 221 85 Lund, Sweden; Klinikum-Bremerhaven, D-27574 Bremerhaven, Germany. Electronic address: per.odin@med.lu.se. · King's College London, and National Parkinson Foundation Centre of Excellence, Dept of Neurology, King's College Hospital, London, UK. · Department of Neurology, University of Kentucky College of Medicine, Kentucky Clinic L-445, 740 South Limestone Street, Lexington, KY 40536-0284, USA. · Department of Neurology, University Hospital of Würzburg, 97080 Würzburg, Germany. · Department of Neurology, Oslo University Hospital and University of Oslo, N-0424 Oslo, Norway. · National Center for Epidemiology and CIBERNED, ISCIII, Avenida Monforte de Lemos 5, 28029 Madrid, Spain. · Department of Neurosurgery, Medizinische Hochschule Hannover, Carl-Neuberg-Strasse 1, 30625 Hannover, Germany. · University Hospital of Bispebjerg, Bispebjerg Bakke 23, 2400 København, NV, Denmark. · Department of Neurology and Karl Landsteiner Institute for Neuroimmunological and Neurodegenerative Disorders, Sozialmedizinisches Zentrum Ost - Donauspital, 1220 Wien Langobardenstraße 122, Austria. · Parkinson and Movement Disorders Unit, IRCCS Hospital San Camillo, Venice, Italy. · Clinical Investigation Center 1436 and Department of Clinical Pharmacology, INSERM and University Hospital of Toulouse, Toulouse University, 37 alées Jules Giesde, 31000 Toulouse, France; Clinical Investigation Center 1436 and Department of Neurosciences, INSERM and University Hospital of Toulouse, Toulouse University, 37 alées Jules Giesde, 31000 Toulouse, France. · Innsbruck Medical University/University Hospital, Anichstrasse 35, A-6020 Innsbruck, Austria. ·Parkinsonism Relat Disord · Pubmed #26233582.

ABSTRACT: Navigate PD was an educational program established to supplement existing guidelines and provide recommendations on the management of Parkinson's disease (PD) refractory to oral/transdermal therapies. It involved 103 experts from 13 countries overseen by an International Steering Committee (ISC) of 13 movement disorder specialists. The ISC identified 71 clinical questions important for device-aided management of PD. Fifty-six experts responded to a web-based survey, rating 15 questions as 'critically important;' these were refined to 10 questions by the ISC to be addressed through available evidence and expert opinion. Draft guidance was presented at international/national meetings and revised based on feedback. Key take-home points are: • Patients requiring levodopa >5 times daily who have severe, troublesome 'off' periods (>1-2 h/day) despite optimal oral/transdermal levodopa or non-levodopa-based therapies should be referred for specialist assessment even if disease duration is <4 years. • Cognitive decline related to non-motor fluctuations is an indication for device-aided therapies. If cognitive impairment is mild, use deep brain stimulation (DBS) with caution. For patients who have cognitive impairment or dementia, intrajejunal levodopa infusion is considered as both therapeutic and palliative in some countries. Falls are linked to cognitive decline and are likely to become more frequent with device-aided therapies. • Insufficient control of motor complications (or drug-resistant tremor in the case of DBS) are indications for device-aided therapies. Levodopa-carbidopa intestinal gel infusions or subcutaneous apomorphine pump may be considered for patients aged >70 years who have mild or moderate cognitive impairment, severe depression or other contraindications to DBS.

2 Guideline Consensus statements on driving in people with Parkinson's disease. 2014

Classen, Sherrilene / Anonymous510792 / Anonymous520792. ·School of Occupational Therapy, Elborn College, Western University, London, Ontario, Canada. ·Occup Ther Health Care · Pubmed #24754762.

ABSTRACT: Parkinson's disease (PD) is a complex neurodegenerative disorder leading to motor and non-motor impairments, all of which can affect fitness to drive. The literature suggest that on-road and simulated driving performances are impaired in people with PD, as compared to healthy control drivers. Clear associations exist between impaired driving performance and contrast sensitivity, visual processing speed, and psychomotor speed. Prior to this review and expert panel process, no evidence-based guidelines have existed to help occupational therapy practitioners determining fitness to drive in those with PD. Three consensus statements are presented in this work to enable occupational therapy practitioners and other driver rehabilitation specialists to make fitness to drive determinations in people with PD.

3 Guideline Consensus-based clinical practice recommendations for the examination and management of falls in patients with Parkinson's disease. 2014

van der Marck, Marjolein A / Klok, Margit Ph C / Okun, Michael S / Giladi, Nir / Munneke, Marten / Bloem, Bastiaan R / Anonymous4170783. ·Radboud university medical center, Nijmegen Centre for Evidence Based Practice, Department of Neurology, Nijmegen, The Netherlands. · University of Florida Center for Movement Disorders and Neurorestoration, Gainesville, FL, USA. · Movement Disorders Unit, Department of Neurology, Tel-Aviv Sourasky Medical Center, Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel. · Radboud university medical center, Nijmegen Centre for Evidence Based Practice, Department of Neurology, Nijmegen, The Netherlands; Radboud university medical center, Nijmegen Centre for Evidence Based Practice, Scientific Institute for Quality of Healthcare, Nijmegen, The Netherlands. · Radboud university medical center, Donders Institute for Brain, Cognition and Behavior, Department of Neurology, Nijmegen, The Netherlands. Electronic address: Bas.Bloem@radboudumc.nl. ·Parkinsonism Relat Disord · Pubmed #24484618.

ABSTRACT: Falls in Parkinson's disease (PD) are common and frequently devastating. Falls prevention is an urgent priority, but there is no accepted program that specifically addresses the risk profile in PD. Therefore, we aimed to provide consensus-based clinical practice recommendations that systematically address potential fall risk factors in PD. We developed an overview of both generic (age-related) and PD-specific factors. For each factor, we specified: best method of ascertainment; disciplines that should be involved in assessment and treatment; and which interventions could be engaged. Using a web-based tool, we asked 27 clinically active professionals from multiple relevant disciplines to evaluate this overview. The revised version was subsequently reviewed by 12 experts. Risk factors and their associated interventions were included in the final set of recommendations when at least 66% of reviewing experts agreed. These recommendations included 31 risk factors. Nearly all required a multidisciplinary team approach, usually involving a neurologist and PD-nurse specialist. Finally, the expert panel proposed to first identify the specific fall type and to tailor screening and treatment accordingly. A routine evaluation of all risk factors remains reserved for high-risk patients without prior falls, or for patients with seemingly unexplained falls. In conclusion, this project produced a set of consensus-based clinical practice recommendations for the examination and management of falls in PD. These may be used in two ways: for pragmatic use in current clinical practice, pending further evidence; and as the active intervention in clinical trials, aiming to evaluate the effectiveness and cost-effectiveness of large scale implementation.

4 Guideline Brazilian Medical Association guidelines for the diagnosis and differential diagnosis of panic disorder. 2013

Levitan, Michelle Nigri / Chagas, Marcos H / Linares, Ila M / Crippa, José A / Terra, Mauro B / Giglio, Alcir T / Cordeiro, Joana L C / Garcia, Giovana J / Hasan, Rosa / Andrada, Nathalia C / Nardi, Antonio E. ·Laboratory of Panic & Respiration, Institute of Psychiatry, Universidade Federal do Rio de Janeiro (UFRJ), Rio de JaneiroRJ, Brazil. · Department of Neurosciences and Behavioral Sciences, Ribeirão Preto Medical School, Universidade de São Paulo (USP), Ribeirão PretoSP, Brazil. · Department of Clinical Medicine: Psychiatry, Universidade Federal de Ciências da Saúde de Porto Alegre (UFCSPA), Porto AlegreRS, Brazil. · Centro de Estudos Jose de Barros Falcão, Porto AlegreRS, Brazil. · Associação Brasileira de Neurologia, Associação Brasileira de NeurologiaBrazil, Brazil. · Associação Médica Brasileira, Associação Médica BrasileiraBrazil, Brazil. ·Braz J Psychiatry · Pubmed #24402216.

ABSTRACT: OBJECTIVE: To present the most relevant findings regarding the Brazilian Medical Association guidelines for the diagnosis and differential diagnosis of panic disorder. METHODS: We used the methodology proposed by the Brazilian Medical Association for the Diretrizes Project. The MEDLINE (PubMed), Scopus, Web of Science, and LILACS online databases were queried for articles published from 1980 to 2012. Searchable questions were structured using the PICO format (acronym for "patient" [or population], "intervention" [or exposure], "comparison" [or control], and "outcome"). RESULTS: We present data on clinical manifestations and implications of panic disorder and its association with depression, drug abuse, dependence and anxiety disorders. In addition, discussions were held on the main psychiatric and clinical differential diagnoses. CONCLUSIONS: The guidelines are proposed to serve as a reference for the general practitioner and specialist to assist in and facilitate the diagnosis of panic disorder.

5 Guideline Managing impulse control behaviours in Parkinson's disease: practical guidelines. 2013

Macphee, Graeme J A / Chaudhuri, K Ray / David, Anthony S / Worth, Paul / Wood, Brian. ·Southern General Hospital, Glasgow, UK. graeme.macphee@ggc.scot.nhs.uk ·Br J Hosp Med (Lond) · Pubmed #23665786.

ABSTRACT: -- No abstract --

6 Guideline Canadian Guidelines on Parkinson's Disease. 2012

Grimes, David / Gordon, Joyce / Snelgrove, Barbara / Lim-Carter, Ivy / Fon, Edward / Martin, Wayne / Wieler, Marguerite / Suchowersky, Oksana / Rajput, Alex / Lafontaine, Anne L / Stoessl, Jon / Moro, Elena / Schoffer, Kerrie / Miyasaki, Janis / Hobson, Doug / Mahmoudi, Minoo / Fox, Susan / Postuma, Ron / Kumar, Hrishikesh / Jog, Mandar / Anonymous2770741. ·Ottawa Hospital, University of Ottawa, Ottawa, Canada. dagrimes@ottawahospital.on.ca ·Can J Neurol Sci · Pubmed #23126020.

ABSTRACT: -- No abstract --

7 Guideline EFNS-ENS Guidelines on the diagnosis and management of disorders associated with dementia. 2012

Sorbi, S / Hort, J / Erkinjuntti, T / Fladby, T / Gainotti, G / Gurvit, H / Nacmias, B / Pasquier, F / Popescu, B O / Rektorova, I / Religa, D / Rusina, R / Rossor, M / Schmidt, R / Stefanova, E / Warren, J D / Scheltens, P / Anonymous1560734. ·Department of Neurological and Psychiatric Sciences, University of Florence, Florence, Italy. sorbi@unifi.it ·Eur J Neurol · Pubmed #22891773.

ABSTRACT: BACKGROUND AND OBJECTIVES: The last version of the EFNS dementia guidelines is from 2007. In 2010, the revised guidelines for Alzheimer's disease (AD) were published. The current guidelines involve the revision of the dementia syndromes outside of AD, notably vascular cognitive impairment, frontotemporal lobar degeneration, dementia with Lewy bodies, corticobasal syndrome, progressive supranuclear palsy, Parkinson's disease dementia, Huntington's disease, prion diseases, normal-pressure hydrocephalus, limbic encephalitis and other toxic and metabolic disorders. The aim is to present a peer-reviewed evidence-based statement for the guidance of practice for clinical neurologists, geriatricians, psychiatrists and other specialist physicians responsible for the care of patients with dementing disorders. It represents a statement of minimum desirable standards for practice guidance. METHODS: The task force working group reviewed evidence from original research articles, meta-analyses and systematic reviews, published by June 2011. The evidence was classified (I, II, III, IV) and consensus recommendations graded (A, B, or C) according to the EFNS guidance. Where there was a lack of evidence, but clear consensus, good practice points were provided. RESULTS AND CONCLUSIONS: New recommendations and good practice points are made for clinical diagnosis, blood tests, neuropsychology, neuroimaging, electroencephalography, cerebrospinal fluid (CSF) analysis, genetic testing, disclosure of diagnosis, treatment of behavioural and psychological symptoms in dementia, legal issues, counselling and support for caregivers. All recommendations were revised as compared with the previous EFNS guidelines. The specialist neurologist together with primary care physicians play an important role in the assessment, interpretation and treatment of symptoms, disability and needs of dementia patients.

8 Guideline National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. 2012

Montine, Thomas J / Phelps, Creighton H / Beach, Thomas G / Bigio, Eileen H / Cairns, Nigel J / Dickson, Dennis W / Duyckaerts, Charles / Frosch, Matthew P / Masliah, Eliezer / Mirra, Suzanne S / Nelson, Peter T / Schneider, Julie A / Thal, Dietmar Rudolf / Trojanowski, John Q / Vinters, Harry V / Hyman, Bradley T / Anonymous470711 / Anonymous480711. ·Department of Pathology, University of Washington School of Medicine, Box 359791, Seattle, WA 98104, USA. tmontine@uw.edu ·Acta Neuropathol · Pubmed #22101365.

ABSTRACT: We present a practical guide for the implementation of recently revised National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease (AD). Major revisions from previous consensus criteria are: (1) recognition that AD neuropathologic changes may occur in the apparent absence of cognitive impairment, (2) an "ABC" score for AD neuropathologic change that incorporates histopathologic assessments of amyloid β deposits (A), staging of neurofibrillary tangles (B), and scoring of neuritic plaques (C), and (3) more detailed approaches for assessing commonly co-morbid conditions such as Lewy body disease, vascular brain injury, hippocampal sclerosis, and TAR DNA binding protein (TDP)-43 immunoreactive inclusions. Recommendations also are made for the minimum sampling of brain, preferred staining methods with acceptable alternatives, reporting of results, and clinico-pathologic correlations.

9 Guideline Clinical practice with anti-dementia drugs: a revised (second) consensus statement from the British Association for Psychopharmacology. 2011

O'Brien, John T / Burns, Alistair / Anonymous2780679. ·Institute for Ageing and Health, Newcastle University, Wolfson Research Centre, Campus for Ageing and Vitality, Newcastle upon Tyne, NE4 5PL, UK. j.t.o'brien@newcastle.ac.uk ·J Psychopharmacol · Pubmed #21088041.

ABSTRACT: The British Association for Psychopharmacology (BAP) coordinated a meeting of experts to review and revise its first (2006) Guidelines for clinical practice with anti-dementia drugs. As before, levels of evidence were rated using accepted standards which were then translated into grades of recommendation A to D, with A having the strongest evidence base (from randomized controlled trials) and D the weakest (case studies or expert opinion). Current clinical diagnostic criteria for dementia have sufficient accuracy to be applied in clinical practice (B) and brain imaging can improve diagnostic accuracy (B). Cholinesterase inhibitors (donepezil, rivastigmine, and galantamine) are effective for mild to moderate Alzheimer's disease (A) and memantine for moderate to severe Alzheimer's disease (A). Until further evidence is available other drugs, including statins, anti-inflammatory drugs, vitamin E and Ginkgo biloba, cannot be recommended either for the treatment or prevention of Alzheimer's disease (A). Neither cholinesterase inhibitors nor memantine are effective in those with mild cognitive impairment (A). Cholinesterase inhibitors are not effective in frontotemporal dementia and may cause agitation (A), though selective serotonin reuptake inhibitors may help behavioural (but not cognitive) features (B). Cholinesterase inhibitors should be used for the treatment of people with Lewy body dementias (Parkinson's disease dementia and dementia with Lewy bodies (DLB)), especially for neuropsychiatric symptoms (A). Cholinesterase inhibitors and memantine can produce cognitive improvements in DLB (A). There is no clear evidence that any intervention can prevent or delay the onset of dementia. Although the consensus statement focuses on medication, psychological interventions can be effective in addition to pharmacotherapy, both for cognitive and non-cognitive symptoms. Many novel pharmacological approaches involving strategies to reduce amyloid and/or tau deposition are in progress. Although results of pivotal studies are awaited, results to date have been equivocal and no disease-modifying agents are either licensed or can be currently recommended for clinical use.

10 Guideline Practice Parameter: treatment of nonmotor symptoms of Parkinson disease: report of the Quality Standards Subcommittee of the American Academy of Neurology. 2010

Zesiewicz, T A / Sullivan, K L / Arnulf, I / Chaudhuri, K R / Morgan, J C / Gronseth, G S / Miyasaki, J / Iverson, D J / Weiner, W J / Anonymous2020653. ·University of South Florida, Tampa, USA. ·Neurology · Pubmed #20231670.

ABSTRACT: OBJECTIVE: Nonmotor symptoms (sleep dysfunction, sensory symptoms, autonomic dysfunction, mood disorders, and cognitive abnormalities) in Parkinson disease (PD) are a major cause of morbidity, yet are often underrecognized. This evidence-based practice parameter evaluates treatment options for the nonmotor symptoms of PD. Articles pertaining to cognitive and mood dysfunction in PD, as well as treatment of sialorrhea with botulinum toxin, were previously reviewed as part of American Academy of Neurology practice parameters and were not included here. METHODS: A literature search of MEDLINE, EMBASE, and Science Citation Index was performed to identify clinical trials in patients with nonmotor symptoms of PD published between 1966 and August 2008. Articles were classified according to a 4-tiered level of evidence scheme and recommendations were based on the level of evidence. RESULTS AND RECOMMENDATIONS: Sildenafil citrate (50 mg) may be considered to treat erectile dysfunction in patients with Parkinson disease (PD) (Level C). Macrogol (polyethylene glycol) may be considered to treat constipation in patients with PD (Level C). The use of levodopa/carbidopa probably decreases the frequency of spontaneous nighttime leg movements, and should be considered to treat periodic limb movements of sleep in patients with PD (Level B). There is insufficient evidence to support or refute specific treatments for urinary incontinence, orthostatic hypotension, and anxiety (Level U). Future research should include concerted and interdisciplinary efforts toward finding treatments for nonmotor symptoms of PD.

11 Guideline Guideline for the treatment of Parkinson's disease. 2009

Carr, J / Kies, B / Fine, J / Anonymous220650. ·jcarr@sun.ac.za ·S Afr Med J · Pubmed #20128276.

ABSTRACT: -- No abstract --

12 Guideline [Consensus statement on deep brain stimulation in Parkinson's disease]. 2009

Anonymous4250637 / Anonymous4260637. · ·Rev Neurol · Pubmed #19728280.

ABSTRACT: INTRODUCTION AND DEVELOPMENT: Deep brain stimulation (DBS) is a surgical technique based on the placement of a programmable electrode into certain areas of central nervous system. DBS is nowadays a well established treatment for patients with Parkinson's disease (PD) and motor complications. However, there are controversies about several items, including the correct selection of patients and the best time for DBS. There is a current trend for DBS to be carried out at earlier stages of PD. A group of experts from Spanish Neurosurgical Society (Functional Surgery Study Group) and Spanish Neurological Society (Movement Disorders Study Group) wrote this consensus statement in order to clarify these and other items.

13 Guideline Deep brain stimulation for Parkinson's disease: Australian referral guidelines. 2009

Silberstein, Paul / Bittar, Richard G / Boyle, Richard / Cook, Raymond / Coyne, Terry / O'Sullivan, Dudley / Pell, Malcolm / Peppard, Richard / Rodrigues, Julian / Silburn, Peter / Stell, Rick / Watson, Peter / Anonymous4620633. ·North Shore Private Hospital, Sydney, New South Wales, Australia. paul@silberstein.com.au ·J Clin Neurosci · Pubmed #19596113.

ABSTRACT: The advent of deep brain stimulation (DBS) has been an important advance in the treatment of Parkinson's disease (PD). DBS may be employed in the management of medication-refractory tremor or treatment-related motor complications, and may benefit between 4.5% and 20% of patients at some stage of their disease course. In Australia, patients with PD are reviewed by specialised DBS teams who assess the likely benefits and risks associated with DBS for each individual. The aim of these guidelines is to assist neurologists and general physicians identify patients who may benefit from referral to a DBS team. Common indications for referral are motor fluctuations and/or dyskinesias that are not adequately controlled with optimised medical therapy, medication-refractory tremor, and intolerance to medical therapy. Early referral for consideration of DBS is recommended as soon as optimised medical therapy fails to offer satisfactory motor control.

14 Guideline [Deep brain stimulation for Parkinson's disease. Consensus recommendations of the German Deep Brain Stimulation Association]. 2009

Hilker, R / Benecke, R / Deuschl, G / Fogel, W / Kupsch, A / Schrader, C / Sixel-Döring, F / Timmermann, L / Volkmann, J / Lange, M / Anonymous2770626. ·Zentrum der Neurologie und Neurochirurgie, Klinik für Neurologie, Goethe-Universität, Frankfurt am Main. ·Nervenarzt · Pubmed #19360386.

ABSTRACT: Deep brain stimulation (DBS) has been shown to be effective for levodopa-responsive symptoms and tremor in Parkinson's disease (PD). The subthalamic nucleus (STN) is the preferred target for most patients suffering from late stage motor complications of the disorder. STN DBS is superior to best medical treatment concerning the control of motor fluctuations and the increase of on-time without dyskinesias. In contrast to DBS of the internal pallidum (GPi), STN stimulation also permits a reduction of the dopaminergic medication. Long-term data demonstrated sustained effectiveness of STN DBS despite progressive disease. DBS of the thalamic ventral intermediate nucleus (VIM) is an alternative target in older PD patients with severe PD tremor refractory to medication. In order to minimize potential risks and side effects, the use of DBS needs careful adherence to inclusion and exclusion criteria for eligible PD patients. This paper summarizes the current consensus recommendations of the German Deep Brain Stimulation Association for DBS in PD.

15 Guideline Pharmacotherapy guidelines for the aged by family doctors for the use of family doctors. 2009

Anonymous3960621 / Bergert, F W / Conrad, D / Ehrenthal, K / Fessler, J / Gross, J / Gundermann, K / Kluthe, B / Lang Heinrich, W / Liesenfeld, A / Loew, P G / Luther, E / Pchalek, R / Seffrin, J / Sterzing, A / Wolfring, H -J / Zimmermann, U. ·Association of Statuatory Health Insurance Physicians in Hesse, Germany. ·Int J Clin Pharmacol Ther · Pubmed #19203528.

ABSTRACT: Part C of the guideline is preceded by Part B General Pharmacology IJCPT. 2008; 46: 600 - 617. Included in Part C are practical guidelines for improving the therapy of some age-specific diseases and problems commonly encountered in general practice. The article in this issue is dedicated to the therapy of Dementia and M. Parkinson. Further guidelines for the other age specific diseases and problems named above will be published in the following issues of IJCPT. An important feature of these guidelines are the inclusion of Levels of Evidence and of the Strength of Recommendations for the therapy which are shown when reliable studies are available. (For both see levels of evidence at the end of this article.).

16 Guideline Re: Practice parameter: assessing patients in a neurology practice for risk of falls (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. 2009

Friedman, Joseph H. · ·Neurology · Pubmed #19171841.

ABSTRACT: -- No abstract --

17 Guideline Practice parameter: Assessing patients in a neurology practice for risk of falls (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. 2008

Thurman, David J / Stevens, Judy A / Rao, Jaya K / Anonymous6930591. ·National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, GA, USA. ·Neurology · Pubmed #18250292.

ABSTRACT: OBJECTIVE: To develop a practice parameter for screening methods and assessments of risk for falls pertaining to patients likely to be seen in neurology practices. METHODS: Relevant literature was systematically reviewed and strength of evidence classified based on the American Academy of Neurology's criteria (Level A: established; Level B: probable; Level C: possible). RESULTS: An increased risk of falls is established among persons with diagnoses of stroke, dementia, and disorders of gait and balance (Level A) and probable among patients with Parkinson disease, peripheral neuropathy, lower extremity weakness or sensory loss, and substantial vision loss (Level B). A history of falling in the past year strongly predicts the likelihood of future falls (Level A). Screening measures have been developed to further assess risks of falls, including functional assessments that may be useful (Levels B and C). Several of these assess overlapping neurologic functions--i.e., gait, mobility, and balance--and there is insufficient evidence to assess whether they offer benefit beyond that provided by a standard neurologic examination. CONCLUSIONS: Patients with neurologic or general conditions associated with an increased risk of falling should be asked about recent falls and further examined for the presence of specific neurologic deficits that predict falls, which include gait and balance disorders; deficits of lower extremity strength, sensation, and coordination; and cognitive impairments. If substantial risks of falls are identified, appropriate interventions that are described in other evidence-based guidelines may be considered.

18 Editorial [Neurological Emergencies: Prompt Identification and Action are Essential]. 2019

Janssens, Uwe. · ·Dtsch Med Wochenschr · Pubmed #30674054.

ABSTRACT: -- No abstract --

19 Editorial When to Start Levodopa Therapy for Parkinson's Disease. 2019

Bressman, Susan / Saunders-Pullman, Rachel. ·From the Icahn School of Medicine at Mt. Sinai, New York. ·N Engl J Med · Pubmed #30673551.

ABSTRACT: -- No abstract --

20 Editorial Taking the 'Disease' out of 'Parkinson's': has the disease had its day? 2019

Worth, Paul F. ·Addenbrooke's Hospital, Cambridge CB2 0QQ, UK paul.worth@addenbrookes.nhs.uk. ·Pract Neurol · Pubmed #30463982.

ABSTRACT: -- No abstract --

21 Editorial Enabling biomarker discovery in Parkinson's disease using multiomics: challenges, promise and the future. 2019

Kiebish, Michael A / Narain, Niven R. ·BERG LLC, Precision Medicine Division, Framingham, MA 01701, USA. ·Per Med · Pubmed #30422077.

ABSTRACT: -- No abstract --

22 Editorial DBS and Impulse Control Disorders in PD: I think we got this…..wait! we don't. 2018

Mehta, Shyamal H. ·Mayo Clinic College of Medicine, Mayo Clinic Arizona, 13400 E. Shea Boulevard, Scottsdale, AZ 85259, United States. Electronic address: mehta.shyamal@mayo.edu. ·Parkinsonism Relat Disord · Pubmed #30558856.

ABSTRACT: -- No abstract --

23 Editorial Behavioural and Cognitive Changes in Lewy Body Dementias. 2018

Kung, Woon-Man / Ho, Ying-Jui / Yoshizawa, Hiroshi / Matsuo, Shinro / Wei, Cheng-Yu. ·Department of Exercise and Health Promotion, College of Education, Chinese Culture University, Taipei, Taiwan. · Division of Neurosurgery, Department of Surgery, Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, New Taipei City, Taiwan. · Department of Surgery, School of Medicine, Buddhist Tzu Chi University, Hualien, Taiwan. · Department of Psychology, Chung Shan Medical University Hospital, Chung Shan Medical University, Taichung, Taiwan. · Department of Neurology, Neurological Institute, Tokyo Women's Medical University, Kawadacho, Shinjuku, Tokyo, Japan. · Department of Nuclear Medicine, Kanazawa University Hospital, Takaramachi, Kanazawa, Japan. · Department of Neurology, Chang Bing Show Chwan Memorial Hospital, Changhua County, Taiwan. ·Behav Neurol · Pubmed #30534208.

ABSTRACT: -- No abstract --

24 Editorial 5-HT 2018

Huot, Philippe. ·Neurodegenerative Disease Group, Montreal Neurological Institute, Montreal, QC H3A 2B4, Canada. · Department of Neuroscience, McGill University, Montreal, QC H3A 2B4, Canada. · Division of Neurology, McGill University Health Centre, Montreal, QC H3A 2B4, Canada. ·Neurodegener Dis Manag · Pubmed #30451579.

ABSTRACT: -- No abstract --

25 Editorial Preface. 2018

Politis, Marios. ·The Neurodegeneration Imaging Group, King's College London. ·Int Rev Neurobiol · Pubmed #30409262.

ABSTRACT: -- No abstract --

Next